Long-term cardiomyopathy risk varies by chemo agent
(HealthDay)—Long-term cardiomyopathy risk varies by chemotherapy agent for childhood cancer survivors, with a decreased risk for daunorubicin versus doxorubicin, according to a study recently publishe
Updated on: April 18,2024
11

Long-term cardiomyopathy risk varies by chemo agent
(HealthDay)—Long-term cardiomyopathy risk varies by chemotherapy agent for childhood cancer survivors, with a decreased risk for daunorubicin versus doxorubicin, according to a study recently publishe
Updated on:April 18,2024
11
